Very high quantitative tumor HER2 content and outcome in early breast cancer

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 2007-2013

  Joensuu, H ^a   Sperinde, J ^b   Leinonen, M ^c   Huang, W ^b   Weidler, J ^b   Bono, P ^a   Kataja, V ^d,e   Kokko, R ^f   Turpeenniemi Hujanen, T ^g   Jyrkkio S ^h   Isola, J ⁱ   Kellokumpu Lehtinen, P L ^j   Paquet, A ^b   Lie, Y ^b   Bates, M ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MONOGRAM BIOSCIENCES   (United States)

^c 4Pharma Ltd   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e VAASA CENTRAL HOSPITAL   (Finland)

^f KANTA HÄME CENTRAL HOSPITAL   (Finland)

^g OULU UNIVERSITY HOSPITAL   (Finland)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

ⁱ TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^j TAMPERE UNIVERSITY HOSPITAL   (Finland)

more..

Author keywords

Adjuvant therapy; Breast cancer; Human epidermal growth factor receptor 2; In situ hybridization; Prognosis; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 80051551694     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq710     Document Type: Article

References (23)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science 1987; 235: 177-182.
2. Browne BC, O'Brien N, Duffy MJ et al. HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets 2009; 9: 419-438.
3. Dowsett M, Procter M, McCaskill-Stevens W et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009; 27: 2962-2969.
4. Sauter G, Lee J, Bartlett JM et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27: 1323-1333.
5. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
6. Larson J, Goodman L, Tan Y et al. Analytical validation of a highly sensitive, accurate, and reproducible assay (HERmark™ for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens. Pathol Res Int 2010; 814176.
7. Lipton A, Koestler W, Leitzl K et al. Quantitative HER2 protein levels predict outcome in FISH-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 2010; 116: 5168-5178.
8. Bates M, Sperinde J, Ali S et al. Identification of a sub-population of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann Oncol 2011; 22: 2014-2020.
9. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
11. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
12. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Cancer Res 2009; 69 (Suppl): 500s (Abstr 62).
13. Joensuu H, Bono P, Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide, with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final analysis of the FinHer trial. J Clin Oncol 2009; 27: 5685-5692.
14. Shi Y, Huang W, Tan Y et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 2009; 18: 11-21.
15. Isola J, Tanner M, Forsyth A et al. Interlaboratory comparison of Her-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004; 10: 4793-4798.
16. Yaziji H, Goldstein LC, Barry TS et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291: 1972-1977.
17. Kerfoot C, Huang W, Rotenberg SA. Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J Histochem Cytochem 2004; 52: 419-422.
18. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004; 5: 465-481.
19. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
20. Baselga J, Carbonell X, Castañeda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-2171.
21. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-5847.
22. Perez EA, Reinholz MM, Hillman DW et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010; 28: 4307-4315.
23. Harigopal M, Barlow WE, Tedeschi G et al. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 2010; 176: 1639-1647.